Compare SLDP & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDP | MDXG |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | 230 | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 535.5M | 607.7M |
| IPO Year | N/A | 2007 |
| Metric | SLDP | MDXG |
|---|---|---|
| Price | $2.35 | $4.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $7.00 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 4.0M | 1.2M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.90 | $13.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $2.21 | $3.03 |
| 52 Week High | $8.86 | $7.99 |
| Indicator | SLDP | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 62.29 |
| Support Level | $2.21 | $3.50 |
| Resistance Level | $2.72 | $5.38 |
| Average True Range (ATR) | 0.13 | 0.16 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 27.03 | 72.58 |
Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.